AU Patent

AU2017239318B2 — Sultam compound and application method thereof

Assigned to Centaurus Biopharma Co Ltd · Expires 2020-08-20 · 6y expired

What this patent protects

Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method therefor, and a pharmaceutical composition containing the compound. The…

USPTO Abstract

Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method therefor, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017239318B2
Jurisdiction
AU
Classification
—
Expires
2020-08-20
Drug substance claim
No
Drug product claim
No
Assignee
Centaurus Biopharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.